Aranidipine

Aranidipine (MPC1304) is a calcium channel antagonist with potent and long-lasting antihypertensive effects. (In Vivo) :Aranidipine (MPC-1304) is a new Ca2+ channel antagonist in spontaneously hypertensive rats. Following oral administration of Aranidipine at doses of 3 and 10 mg/kg to spontaneously hypertensive rats (SHR), there are significant decreases in Bmax values for specific [3H] (+) -PN 200-110 binding to myocardial membranes compared to the control values. The Bmax values at 1 h (3 mg/kg), 1 and 6 h (10 mg/kg) are significantly decreased (47.7, 48.9 and 25.8%, respectively) compared to the control values. The effect is greatest at 1 h and decreases with time. The Bmax values at 6 h (3 mg/kg) and 12 or 24 h (10 mg/kg) after the oral administration of Aranidipine are not significantly different from the control values, suggesting the disappearance of the effect of Aranidipine. The Kd values for myocardial [3H] (+) -PN 200-110 binding are unaltered by oral administration of Aranidipine.

86780-90-7

MPC1304

Pharmacology & Drug Discovery

>98% (HPLC)

DMSO:10 mM

COC (=O) C1=C (C) NC (C) =C (C1c1ccccc1[N+] ([O-]) =O) C (=O) OCC (C) =O

C19H20N2O7

388.37

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.